Q2 2021

Source filing unavailable

Q2 2021 · —

Revenue—

Net Income

-$6.34M

N/M vs Q2 2020

EPS Diluted

-$0.26

no prior Q2 2020 on file

Operating Income-$5,612,380—

Operating Cash Flowderived-$3,420,214—

Free Cash Flowderived

Same quarter

Metric	Q2 2021	Q2 2020
Net Income	-$6.34M	-$4.27M
EPS Diluted	-$0.26	—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

MiNK Therapeutics, Inc. · CIK 1840229 · Engraved from SEC EDGAR